Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07412197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preventive Dendritic Cell Vaccination for Lynch Syndrome

Study acronym: PREVENT-Lynch
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from Radboud University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modifiedv3 Show 4 more changesShow less
    • Start date: Aug 2026 to Oct 2026
    • Enrollment increased: 13 → 16 participants
    • Secondary endpoints revised (3)
    • Study description revised
  2. Primary endpoint(s) modifiedv2 Show 4 more changesShow less
    • Enrollment reduced: 23 → 13 participants
    • Start date: Jun 2026 to Aug 2026
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 5 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess safety, immunogenicity and feasibility of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.
Trial Details
NCT Number NCT07412197
Lead Sponsor Radboud University Medical Center
Collaborators: Dutch Cancer Society
Conditions
(from sponsor)		 Lynch Syndrome
Related terms Colorectal Neoplasms, Hereditary Nonpolyposis
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov